Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

The pipeline includes adeno-associated virus-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis and retinitis pigmentosa.

GNSC-001 is an investigational, adeno-associated virus gene therapy expressing an optimized form of IL-1Ra. The Food and Drug Administration (FDA) has granted Fast Track designation to GNSC-001 for ...

The company said the case was “consistent with known risks” of gene therapies that use a benign adeno-associated virus, or ...

A team of researchers from Queen Mary University of London and institutions in Beijing has developed a promising virus-based ...

Researchers from Queen Mary University of London, the Chinese Academy of Sciences and Capital Medical University in Beijing ...

Virus linked to common cold could help treat aggressive brain tumours - Scientists say new approach offers ‘a way forward’ ...

Cancer-killing virus treatment shows promise against brain tumour - Glioblastoma is the most common and fatal type of brain ...

A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for ...

About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic ...